Liquid Ursodeoxycholic Acid

In 2016, we acquired rights to a liquid formulation of ursodeoxycholic acid that we are developing for the treatment of a small group of patients living with a rare liver disease called primary biliary cholangitis (PBC).

While maintaining a healthy lifestyle may help relieve or prevent some PBC symptoms, this chronic disease is most often treated with ursodeoxycholic acid (which is also known as ursodiol or UDCA).1 Currently, this bile acid is prescribed only in solid forms, such as a tablets or capsules.2 Introducing a liquid formulation of ursodeoxycholic acid would provide healthcare professionals with a dosing alternative for patients who have difficulty swallowing.2

Activities are underway with the intention of making a liquid formulation commercially available in the United States. If approved, we plan to market the treatment for the subset of people with PBC who have difficulty swallowing.

Request more information about Liquid Ursodeoxycholic Acid.



  1. American Liver Foundation. Primary Biliary Cholangitis (PBC, Primary Biliary Cirrhosis). Available at: Last accessed July 28, 2016.
  2. Setchell, et al. Aliment Pharmacol Ther 2005; 21: 709–721.